We get an important update from Lilly today about when it plans to file for regulatory approval for its next generation, next generation weight loss shot, read a true tide, which is going to be a pretty big product for Lilly if it ends up being approved already. There are a lot of people seeking out black market versions of this drug, just because they've heard about all of the potentially incredible effects, everything from 30% up to 30%, weight loss to liver impacts and all of these other potential health ...

Market Trends & Macroeconomy - Wall Street extended previous losses as major averages declined, with the 10-year Treasury yield topping **4.7%**, marking the highest level since January **2025** [1] - The Dow Jones Industrial Average plunged nearly **600 points** (specifically **591 points** or over **1%**), and the S&P 500 index dropped **77 points** (over **1%**) [1][2] - The NASDAQ index tanked **450 points** or **1.75%** (**1 and 3/4%**), with chipmakers mostly in the red except for Micron, which rose almost **2%** [2] - The national average for a gallon of regular gasoline increased by **3 cents** overnight to reach **$49** per gallon (Note: transcribed as **$49** in source text), driven by rising crude prices [4] - Mortgage rates rose toward **7%**, with the average rate on a **30-year** fixed home loan sitting at **6.77%** based on Mortgage News Daily data [5] - Initial weekly unemployment benefit applications fell to **187,000**, marking the lowest weekly number since the late **1960s** [7][8] Industry Dynamics & Corporate Performance - Google parent Alphabet shares dropped **5.5%** after reporting quarterly results, weighed down by heavy AI spending that overshadowed growth [1][5] - Brent crude oil approached **$100** a barrel (topping **$100** as the world's benchmark), while U.S. crude topped **$90** a barrel amid escalating Middle East tensions involving Saudi Arabian tankers [2][4] - IBM shares declined following disappointing quarterly results, coming after a preliminary release that triggered the largest sell-off in the company's history, with IBM losing a quarter of its value [6] - Eli Lilly is set to file for approval for its next-generation obesity drug, Retatrutide, next year following successful trial clearances, positioning it as a potentially more effective weekly injection [9]